A5079751241- Renal cell carcinoma treatment
- Bladder and Urothelial Cancer Treatments
- Cancer Immunotherapy and Biomarkers
- Renal and related cancers
- Pancreatic and Hepatic Oncology Research
- Cancer Genomics and Diagnostics
- Photonic and Optical Devices
- Multiple and Secondary Primary Cancers
- Economic and Financial Impacts of Cancer
- Renewable energy and sustainable power systems
- Building energy efficiency and sustainability
- Optical Network Technologies
- Inflammatory Biomarkers in Disease Prognosis
- Analytical Chemistry and Sensors
- Pediatric Urology and Nephrology Studies
- Receptor Mechanisms and Signaling
- Advanced Photonic Communication Systems
- Urological Disorders and Treatments
- Cardiac Arrhythmias and Treatments
- Nutrition and Health in Aging
- Neuropeptides and Animal Physiology
- Renal and Vascular Pathologies
- Urinary and Genital Oncology Studies
- GaN-based semiconductor devices and materials
- Microgrid Control and Optimization
Tokyo Women's Medical University Adachi Medical Center
2021-2025
Tokyo Women's Medical University
2016-2025
Eisai (Japan)
1990-2024
Mitsubishi Electric (Japan)
2020-2024
Hokkaido University
2009-2024
Shimane University
2023
Shizuoka University
2011-2022
Kyoto Katsura Hospital
2021-2022
Kyoto University
2021-2022
Toyama Prefectural Agricultural, Forestry & Fisheries Research Center
2020
We synthesized various 4-benzylamino-1-chloro-6-substituted phthalazines (15) and 4-benzylamino-1-chloro-7-substituted (16) evaluated their inhibitory activity toward phosphodiesterase 5 (PDE5) purified from porcine platelets. The PDE5-inhibitory activities of 15 were greater than those the isomers (16). preferred substituent at 4-position phthalazine was a (3-chloro-4-methoxybenzyl)amino group, 6-position cyano, nitro, trifluoromethyl groups. Compounds 15a (IC50 = 4.8 nM), 15f (3.5 15i (5.3...
Left atrial appendage (LAA) thrombosis is an important cause of cardiogenic cerebral thromboembolism. Apixaban a member the class novel oral anticoagulants (NOAC) and superior to warfarin in preventing stroke or systemic embolism, causes less bleeding, results lower mortality patients with fibrillation. There are few reports resolution LAA thrombus other NOAC. We present 72-year-old male patient persistent fibrillation associated left thrombus. Sixteen days apixaban treatment showed complete...
In this paper, we will demonstrate the value of olefin cross metathesis as an effective synthetic tool for applications in agrochemical and pharmaceutical industries. First, usefulness reactions efficient synthesis major component Peach Twig Borer pheromone Omnivorous Leafroller pheromone, insect pheromones are environmentally friendly pest-controlling agents. Second, highly routes into novel α,β-unsaturated carbonyl intermediates. These intermediates can be further functionalized compounds...
New pathological subtypes of renal cell carcinoma (RCC) were designated in the 2016 World Health Organization (WHO) classification corresponding to features commonly seen patients with end‐stage disease (ESRD). To determine clinicopathological findings new subtypes, we reanalyzed all sections from 315 kidneys 291 ESRD bearing RCC tumors surgically resected three Japanese institutes by central pathologist. Clear was diagnosed 144 (45.7%), acquired cystic (ACD)‐associated 100 (31.7%),...
Long-term follow-up data regarding treatment outcomes of nivolumab plus ipilimumab combination therapy for advanced renal cell carcinoma as a first-line are limited in real-world Japanese populations.
Cancer cachexia is associated with a poor prognosis. This study aimed to investigate the association between sarcopenia and survival in patients metastatic hormone-sensitive prostate cancer.We retrospectively evaluated 197 diagnosed cancer our department its affiliated institution January 2008 December 2015. Sarcopenia was according sex-specific consensus definition. Castration-resistance cancer-free survival, cancer-specific overall from diagnoses were calculated using Kaplan-Meier method...
The efficacy of immune checkpoint inhibitor (ICI) combinations in treating inferior vena cava (IVC) tumour thrombi has not yet been reported. We aimed to evaluate the clinical ICIs for patients with renal cell carcinoma (RCC) and a concomitant IVC thrombus.Three men two women RCC an thrombus were administered 2020-2021. Three received nivolumab plus ipilimumab pembrolizumab axitinib therapy, respectively.All ICI-treated showed shrinkage. level was downstaged patients. mean reduction maximum...
Abstract This study proposes an active vibration control technique for pipe structures using dielectric elastomer actuators (DEAs). Vibrations in must be eliminated to improve their mechanical reliability, and techniques can applied effective suppression. Soft actuators, which completely fit with complex-shaped surfaces, are required transfer reduction forces the target. DEA is suitable this kind of target structure because characterized by high stretchability, flexibility, large...
Abstract Purpose Combined immunotherapy of nivolumab plus ipilimumab for intermediate- and poor-risk metastatic clear cell renal carcinoma showed prolonged progression-free survival high objective response rate in a randomized phase III clinical trial. However, the efficacy this treatment papillary remains unclear. In present study, we analysed therapy compared with that carcinoma. Materials Methods This is retrospective study 30 patients who received as first-line between December 2015 May...
Background/Aim: We investigated the prognostic nutritional index (PNI), comprised of lymphocytes and albumin, as a potential prognosticator metastatic urothelial carcinoma (mUC) patients receiving pembrolizumab. Patients Methods: Sixty-five were retrospectively enrolled classified low (<40) high (≥40) based on pretreatment PNI. Progression-free survival (PFS), overall (OS) response rates evaluated. Results: In PNI group, significantly shorter PFS OS observed. was shown to be an...
Scarce data are available on the changes in outcomes related to advanced renal cell carcinoma (RCC), from previous tyrosine kinase inhibitor (TKI) era current immuno-oncology (IO) era, among patients IMDC favorable-risk group. Among 618 with previously untreated RCC according our database, 72 classified an International Metastatic Database Consortium (IMDC) favorable risk were selected. These divided into two groups (IO and TKI eras) based treatments recognized as standard of care at time...